In an interview with Yahoo Finance, Deutsche Bank analyst James Shin singled out Roche’s (OTCMKTS: RHHBY) drug “CT-996” when asked about which oral weight loss drug he sees as the biggest ...

In an interview with Yahoo Finance, Deutsche Bank analyst James Shin singled out Roche’s RHHBY drug “CT-996” when asked about which oral weight loss drug he sees as the biggest threat to ...

Detailed price information for Structure Therapeutics Inc (GPCR-Q) from The Globe and Mail including charting and trades.

The company presented data for two of its recently acquired obesity assets, CT-996 (oral) and CT-388 (injectable), at the European Association for the Study of Diabetes (EASD) conference in Madrid.

In a presentation to investors, the Swiss drugmaker said the revenue projection applies on aggregate to weekly injection CT-388 – which is similar to Eli Lilly’s Zepbound – and daily pill CT-996 as ...